I

Ionis Pharmaceuticals
D

IONS

33.980
USD
0.04
(0.12%)
Market Closed
Volume
75,531
EPS
-4
Div Yield
-
P/E
-14
Market Cap
5,365,349,812
OverviewSignalsIdeasNews
Related Instruments
    A
    ACAD
    -0.240
    (-1.41%)
    16.790 USD
    ALNY
    ALNY
    -22.650
    (-8.77%)
    235.480 USD
    BIIB
    BIIB
    -4.840
    (-2.94%)
    160.000 USD
    B
    BMRN
    -2.200
    (-3.35%)
    63.440 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    VRTX
    VRTX
    -18.53
    (-3.83%)
    450.72 USD
    More
News

Title: Ionis Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.